MESOBLAST Aktie

 

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The event will be webcast live from 8:00am to 11:00am EST and will include presentations from Mesoblast's senior leadership team and from key opinion leaders....

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs in new pediatric and adult inflammatory conditions in partnership with investigators and key opinion leaders....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

This biotech was up almost 9% before sinking into the red. The post What's going on with Mesoblast shares today? appeared first on The Motley Fool Australia....

Mesoblast posts strong H1 FY2026 results on the back of Ryoncil®'s US launch and robust revenue growth. The post Mesoblast shares: Revenue surges on Ryoncil® US launch in H1 FY2026 appeared first on The Motley Fool Australia....

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025....

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the February 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah....

Bell Potter thinks this biotech could be cheap and heading much higher. The post Could Mesoblast shares hit $4.45 in 2026? appeared first on The Motley Fool Australia....

Mesoblast shares slip after its quarterly update, as investors focus on cash flow and execution. The post This ASX 200 stock just reported a milestone quarter. So why are its shares falling? appeared first on The Motley Fool Australia....

Mesoblast posts strong Ryoncil sales and secures new funding, with cash reserves set for upcoming clinical milestones. The post Mesoblast posts revenue jump and new funding: Key takeaways for investors appeared first on The Motley Fool Australia....

NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryoncil® (remestemcel-L-rknd) since commercially available in March 2025 for the approved label in children 2 months and older with steroid-refractory acute graft-versus-host disease (SR-aGvHD). Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food & Drug Administration (FDA) for any indication.1...

Mesoblast (ASX:MSB) has seen its shares dip on Monday morning out the…...

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product. The post Mesoblast just cleared a key FDA hurdle. So why are investors exiting? appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Mesoblast (ASX:MSB) is back onto investors' radars after the slower Christmas period,…...

These shares are ending the week strongly. But why? The post Why Codan, DroneShield, Mesoblast, and Woodside shares are storming higher today appeared first on The Motley Fool Australia....

This biotech is hitting new highs on Friday. Let's find out why. The post Why are Mesoblast shares jumping 10% to a 52-week high? appeared first on The Motley Fool Australia....

NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the Company's evolution to a revenue-generating commercial company....

These shares are having a good session on Tuesday. Let's see why. The post Why DroneShield, IPD, Mesoblast, and Woodside shares are charging higher today appeared first on The Motley Fool Australia....